JPRN-UMIN000007221
Completed
未知
Multicenter Clinical Study Evaluating the Safety and Efficacy of Dasatinib Treatment and its Discontinuation in Patients with Chronic Phase Chronic Myelogenous Leukemia who had Reached Complete Molecular Response during Imatinib Therapy - Multicenter Clinical Study on the Safety and Efficacy of Dasatinib Discontinuation
Juntendo University School of Medicine0 sites40 target enrollmentStarted: February 3, 2012Last updated:
Overview
- Phase
- 未知
- Status
- Completed
- Sponsor
- Juntendo University School of Medicine
- Enrollment
- 40
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Concurrent malignancy other than CML 2\.Women who are pregnant or breastfeeding 3\. A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy
Investigators
Similar Trials
Active, not recruiting
Phase 1
A multi-centre clinical trial evaluating safety and patients' ability to independently use the medicinal product indicated in the treatment of erectile dysfunctioEUCTR2019-003073-25-PLAdamed Pharma S.A.400
Completed
Phase 2
A Multi-Centre Clinical Study to Evaluate the Safety and Effectiveness of the ESS505® Device to Prevent Pregnancy in Women Who Are Seeking Permanent ContraceptioWomen ages range 21 to 44 years desiring permanent contraceptionbirth controlcontraceptionNL-OMON39616Bayer40
Active, not recruiting
Not Applicable
n-blinded Multicenter Study of Robotic-assisted Laparoscopic Partial NephrectomycT1 Renal CancerJPRN-jRCT1052190004Masato Fujisawa100
Active, not recruiting
Phase 1
Safety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fractioHeart failure with reduced ejection fractionMedDRA version: 20.0 Level: LLT Classification code 10019279 Term: Heart failure System Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2014-001971-30-PTovartis Pharma services AG1,980
Active, not recruiting
Phase 1
Safety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fractioEUCTR2014-001971-30-FIovartis Pharma services AG5,000